Latest uniQure News & Updates

See the latest news and media coverage for uniQure. We track all announcements, press releases, and industry mentions in real time, all in one place.

uniQure

Gene therapy company targeting neurological and rare diseases

uniqure.com

Headquarters: Amsterdam, Netherlands
Founded year: 1998
Company type: Public company
Number of employees: 200–340
Industry: Biotechnology & Medical Research

Last updated October 28

Latest news about uniQure

In short: uniQure filed a BLA for its Huntington's gene therapy after the FDA reversed course and accepted its application

Company announcements

October 28 uniQure

uniQure announces third quarter 2026 financial results

Results report on November 4 before market open. An earnings call follows at 8:30 AM ET via webcast or phone.

September 2 uniQure

uniQure submits applications for Huntington's gene therapy

The company filed a BLA with the FDA and an MAA with the UK MHRA for ifezuntirgene inilparvovec based on three-year clinical data.

July 29 uniQure

uniQure reports Q2 2026 financial results and company update

The company raised $259 million, securing cash until 2030. BLA for AMT-130 targets Q3 2026. Net loss widened to $81.1 million.

June 25 uniQure

uniQure raises approximately $259 million in public offering

The company upsized the offering by exercising the underwriters' option for additional shares at $45.50 per share to fund commercialization and R&D.

Media coverage

October 17 Ad Hoc News

uniQure reported AMT-130 data as uniQure stock faces FDA review

uniQure N.V. reported that AMT-130 slowed Huntington's disease progression by 44.00 percent after 48 months, compared with 75.00 percent after 36 months. The update dated...

September 29 Rare Disease Advisor

Ifezuntirgene Inilparvovec, uniQure’s HD Gene Therapy, Slows Functional Decline Through Month 48

At month 48, uniQure’s experimental gene therapy for Huntington disease (HD) continued to slow functional decline as measured ...

September 29 Zone Bourse

UniQure N.V. announces new data from ongoing phase I/II studies on ifezuntirgene inilparvovec in Huntington's disease

uniQure N.V. announced new data from ongoing phase I/II studies on ifezuntirgene inilparvovec in the treatment of Huntington's disease...

September 28 Bloomberg

UniQure Huntington's Treatment Benefit Is Less After Four Years

UniQure NV slumped in early trading after reporting that the benefits of its Huntington's disease gene therapy drug AMT-130 were not as good after four...

Never miss news about uniQure

Track uniQure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

uniQure competitors & trending companies

Browse news for competitors to uniQure and other trending companies.